Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience
JCO Precision Oncology · 2023-08 · (7)
DOI: 10.1200/po.22.00706 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2023-08. Verfasst von Tucker Coston und 10 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Jacksonville, FL. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Pancreatic cancer (PC) carries a poor prognosis with high rates of unresectable/metastatic disease at diagnosis, recurrence after resection, and few systemic therapy options. Deficient mismatch repair (dMMR)/high microsatellite instability (MSI-H) PCs demonstrated uncharacteristically poor outcomes in KEYNOTE-158, evaluating pembrolizumab in MSI-H solid tumors. Our study aggregates the Mayo Clinic experience with dMMR/MSI-H PCs, characterizing the clinical, molecular, and treatment response patterns with a focus on response to immune checkpoint inhibitors (ICIs). METHODS Retrospective data were collected from the electronic medical record from December 2009 to February 2023. Patients were included if they had a pathologically confirmed pancreatic malignancy and had (1) deficient expression of mismatch repair (MMR) proteins by tumor immunohistochemistry, (2) pathogenic mutation of MMR genes on genomic sequencing, and/or (3) MSI-H by polymerase chain reaction. RESULTS Thirty-two patients were identified for inclusion, with all stages of disease represented. Sixteen of these patients underwent surgery or chemoradiotherapy. Of these patients, uncharacteristically favorable responses were seen, with a recurrence rate of only 19% (n = 3) despite a median follow-up of 25 months. In the palliative setting, excellent responses to ICI were seen, with overall response rate (ORR) of 75% (20% complete response). Median time to disease progression was not reached. Response rates to cytotoxic chemotherapy in the palliative setting were poor, with 30% ORR and median time to progression of 4 months. We observed a high rate of discrepancy between MMR and MSI testing methods, representing 19% of the entire cohort and 26% of evaluable cases. CONCLUSION Our data argue for the preferential use of ICI over cytotoxic chemotherapy in any patient with dMMR/MSI-H PC requiring systemic therapy, including in the metastatic and adjuvant/neoadjuvant settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mayo Clinic, Jacksonville, FL.
- Mayo Clinic, Rochester, MN.
- Mayo Clinic, Phoenix, AZ.
- University Hospitals Cleveland Medical Center, Cleveland, OH.
- Cleveland Clinic Taussig Cancer Center, Cleveland, OH.
ORCID-Profile: Tucker Coston, Aakash Desai, Hani Babiker, Mohamad Bassam Sonbol, Sakti Chakrabarti, Amit Mahipal, Robert McWilliams, Wen Wee Ma, Tanios S Bekaii-Saab, John Stauffer, Jason S Starr
Zitieren
APA
Coston, T., Desai, A., Babiker, H., Sonbol, M. B., Chakrabarti, S., Mahipal, A., McWilliams, R., Ma, W. W., Bekaii-Saab, T. S., Stauffer, J., & Starr, J. S. (2023). Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience. JCO Precision Oncology. https://doi.org/10.1200/po.22.00706
Vancouver
Coston T, Desai A, Babiker H, Sonbol MB, Chakrabarti S, Mahipal A, et al. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience. JCO Precision Oncology. 2023. doi:10.1200/po.22.00706
BibTeX
@article{Coston2023,
author = {Coston, Tucker and Desai, Aakash and Babiker, Hani and Sonbol, Mohamad Bassam and Chakrabarti, Sakti and Mahipal, Amit and McWilliams, Robert and Ma, Wen Wee and Bekaii-Saab, Tanios S and Stauffer, John and Starr, Jason S},
title = {Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience},
journal = {JCO Precision Oncology},
year = {2023},
number = {7},
doi = {10.1200/po.22.00706}
}
EUVIMED